Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism? (Q34366087)

1 August 2017

title

Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism? (English)

1 reference

1 August 2017

0 references

1 reference

3

Piergiorgio Messa

1 reference

1 August 2017

João M Frazão

1

1 reference

1 August 2017

Johann Braun

2

1 reference

1 August 2017

Bastian Dehmel

4

1 reference

1 August 2017

Caroline Mattin

5

1 reference

1 August 2017

Martin Wilkie

6

1 reference

1 August 2017

language of work or name

1 reference

3 August 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

13

1 reference

1 August 2017

page(s)

76

1 reference

Creative Commons Attribution 2.0 Generic

1 August 2017

copyright license

start time

3 August 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84)

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Consistent control of mineral and bone disorder in incident hemodialysis patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Hyperphosphatemia of chronic kidney disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

The mechanism of phosphorus as a cardiovascular risk factor in CKD

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

PARATHYROID HYPERPLASIA IN RABBITS PRODUCED BY PARENTERAL PHOSPHATE ADMINISTRATION.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

BONE RESORPTION IN TISSUE CULTURE. FACTORS INFLUENCING THE RESPONSE TO PARATHYROID HORMONE.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Phosphate regulation of vascular smooth muscle cell calcification

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Pathogenesis of secondary hyperparathyroidism

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Calcimimetics with potent and selective activity on the parathyroid calcium receptor

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis

6 July 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2369-13-76

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2369-13-76

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2369-13-76

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2369-13-76

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2369-13-76

First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2369-13-76

Dynamics of parathyroid hormone secretion after total parathyroidectomy and autotransplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2369-13-76

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2369-13-76

K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473247

Fracture risk after parathyroidectomy among chronic hemodialysis patients

27 October 2018

1 reference

12 December 2020

Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder

1 reference

12 December 2020

Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients

1 reference

12 December 2020

Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)

1 reference

12 December 2020

Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units

1 reference

12 December 2020

Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study

1 reference

12 December 2020

Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study

1 reference

12 December 2020

Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQITM ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2369-13-76

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference

1 August 2017

1 reference